Levobupivacaína Altan (Levobupivacaine)

Levobupivacaine blocks voltage‑gated sodium channels on neuronal membranes, preventing sodium influx that is essential for depolarisation. This reversible inhibition stops the generation and propagation of nerve impulses, leading to loss of sensation and, at higher concentrations, motor block in the area supplied by the targeted nerves.

The dose of Levobupivacaína Altan is determined by the prescribing clinician based on the type of procedure, the route of administration, patient weight, age, and comorbidities. Clinicians select an appropriate concentration and volume to achieve the desired anesthetic effect while monitoring for toxicity.

Safety data for levobupivacaine in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under close medical supervision. Breastfeeding mothers should consult their healthcare provider before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if required) and assist with import documentation.

Levobupivacaine is the S‑enantiomer of bupivacaine and offers a similar duration of anesthesia with a lower risk of cardiotoxicity and central nervous system toxicity. Both agents provide long‑acting block, but levobupivacaine is often preferred when a safer cardiovascular profile is desired.

Store the product at ambient temperature, preferably below 25 °C, in its original sealed container. Protect it from direct sunlight, moisture and extreme temperatures. Do not freeze. Inspect the vial for particulate matter before use and discard if the solution appears discoloured or contaminated.

Levobupivacaína Altan is administered by a qualified healthcare professional via epidural, intrathecal, infiltration or peripheral nerve block techniques. The solution is injected directly into the target space using aseptic technique, with dose and volume adjusted to the clinical situation and patient response.

The most serious risks include cardiovascular toxicity such as arrhythmias, severe hypotension or cardiac arrest, and central nervous system toxicity including seizures, loss of consciousness, and respiratory depression. Prompt recognition and supportive management are essential if systemic toxicity occurs.

Levobupivacaína Altan should be avoided in patients with known hypersensitivity to amide‑type local anesthetics, those with severe hepatic impairment, uncorrected hypovolemia, or significant cardiac conduction abnormalities. It is also contraindicated when inadvertent intravascular injection cannot be reliably prevented.